Please login to the form below
larotrectinib
This page shows the latest larotrectinib news and features for those working in and with pharma, biotech and healthcare.
Immuno-oncology, personalised medicine continues to drive pharma sector
A recent example of this issue is Bayer’s tumour-agnostic drug Vitrakvi (larotrectinib), which targets all solid tumours that display a NTRK gene fusion regardless of cancer type, but was
Latest news
-
NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
In a blow to Bayer, NICE also said in the statement that Roche’s Vitrakvi (larotrectinib) rival Rozlytrek (entrectinib) could instead become the first histology independent treatment to be made available ... In its draft guidance, the NICE committee
-
Lilly expands dermatology portfolio with $1.1bn Dermira deal
From that deal, Lilly gained TRK inhibitor Vikrakvi (larotrectinib), a targeted cancer drug for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours with a neurotrophic
-
Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval
Will likely face competition soon from rival Rozlytrek. Bayer’s Vitrakvi (larotrectinib) has become the first tumour-agnostic drug in Europe to be approved for the treatment of cancer.
-
Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO
The company has just picked up a new approval for targeted cancer drug Rozlytrek(entrectinib), a rival to Bayer’s Vitrakvi (larotrectinib), and for anti-CD79b antibody drug conjugate Polivy (polatuzumab
-
Roche undercuts price of Bayer cancer drug after winning FDA approval
Both drugs highly effective in small subset of patients. Roche has won US Food and Drug Administration (FDA) approval for its rival to Bayer’s oncology drug Vitrakvi (larotrectinib).
More from news
Approximately 2 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
Vitrakvi(larotrectinib) gained FDA approval in late November to treat any solid tumours that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, which causes the production of TRK, a family ... In Europe, a marketing application for
-
Cancer immunotherapy: What's on the horizon?
also extending to targeted cancer drugs, with Loxo Oncology and Bayer’s larotrectinib filed for TRK gene fusion tumours and due for an FDA verdict in November.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Account Director
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Senior Account Manager
-
Competitive
-
Medical Editor
-
Competitive
- Sinovac’s COVID-19 vaccine appears safe in older adults
- PHE study finds people who have had COVID-19 can still transmit the virus
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- PHE study finds people who have had COVID-19 can still transmit the virus
- Inovio plans late-stage COVID-19 vaccine study in second quarter 2021
- AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine
- EU proposes vaccine-sharing mechanism with low-income countries
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- WHO’s director-general deems vaccine nationalism a “catastrophic moral failure”
- Lilly partners with Merus on development of bispecific antibodies for cancer
- Medical research charities need our help – support is needed to continue funding life-saving research and improving lives
- Research Partnership appoints Hannah Osborn to MedTech director role
PMHub
EPG Health
REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...
Latest intelligence
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- Recent years have seen a significant shift in drug development to specialty areas...
- 2020 - a year to remember or forget?
- 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
- The search for effective drug treatments for COVID-19
- PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
Quick links
Infographics
